AKT mediates actinomycin D-induced p53 expression.

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Actinomycin D (ActD) exhibits distinct effects on p53 stabilization at high (cytotoxic) and low (cytostatic) concentrations.
• High ActD concentrations inhibit transcription, reducing MDM2 and stabilizing p53.
• Low ActD concentrations induce ribosomal stress, decreasing MDM2 activity and activating p53.

Purpose of the Study:

• To elucidate the molecular pathways responsible for Actinomycin D-induced p53 expression.
• To investigate the role of specific signaling pathways, including PI3K/AKT and MAPKs, in mediating ActD's effects on p53.
• To assess the therapeutic potential of ActD in p53-based cancer cyclotherapy.

Main Methods:

• Utilized specific inhibitors (LY294002, wortmannin, deguelin) targeting phosphatidylinositol 3-kinases (PI3K) and AKT.
• Employed RNA interference (small hairpin RNA-AKTs) to downregulate AKT expression.
• Assessed p53 expression levels and AKT phosphorylation status (Ser473) in response to ActD treatment.

Main Results:

• Inhibitors of PI3K and AKT, but not MEK1/2, JNK, or p38-MAPK, abolished ActD-induced p53 expression across various cell types.
• Downregulation of AKT via RNA interference significantly decreased ActD-induced p53 expression.
• ActD treatment led to increased AKT phosphorylation at Ser473, indicating its full activation.

Conclusions:

• The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is crucial for mediating Actinomycin D-induced p53 stabilization and activation.
• ActD's ability to modulate p53 through the PI3K/AKT pathway highlights its potential as a therapeutic agent in p53-based cancer cyclotherapy.
• Further investigation into ActD's mechanism of action could lead to novel cancer treatment strategies.